B002 in Patients With HER2-positive Breast Cancer (B002-101)
Experimental Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of B002 in the Treatment of HER2-positive Recurrent or Metastatic Breast Cancer.
Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd
This PHASE1 trial investigates Metastatic Breast Cancer and Recurrent Breast Cancer and is currently completed. Shanghai Pharmaceuticals Holding Co., Ltd leads this study, which shows 9 recorded versions since 2019 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Apr 2023 — Jul 2024 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Mar 2023 — Apr 2023 [monthly]
Recruiting PHASE1
-
Nov 2022 — Mar 2023 [monthly]
Recruiting PHASE1
▶ Show 4 earlier versions
-
Sep 2022 — Nov 2022 [monthly]
Recruiting PHASE1
-
Jan 2021 — Sep 2022 [monthly]
Recruiting PHASE1
-
Aug 2020 — Jan 2021 [monthly]
Recruiting PHASE1
-
Jun 2020 — Aug 2020 [monthly]
Recruiting PHASE1
First recorded
May 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Shanghai Pharmaceuticals Holding Co., Ltd
For direct contact, visit the study record on ClinicalTrials.gov .